Riboxx GmbH
The drug products of riboxx pharmaceuticals belong to the class of Toll-like-Receptor 3 agonists (TLR) and RIG-I-like-Receptor (RLR) agonists. The drug substance is RNA (ribonucleic acid). Our GMP TLR3 ligands (RIBOXXIM®, APOXXIM®, RIBOXXON®, RIBOXXOL®) are available for pharmaceutical companies or public institutions performing Phase I to III clinical trials.
Basic Information
- Category: business
- Website: https://www.riboxx.com/
Evidence and Sources
- Riboxx GmbH — Official Website (official)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Riboxx GmbH.
- Canonical profile: https://brandsource.ai/brands/riboxx-gmbh
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/riboxx-gmbh/json-ld
- Citation profile API: https://brandsource.ai/api/brands/riboxx-gmbh/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (74/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
The drug products of riboxx pharmaceuticals belong to the class of Toll-like-Receptor 3 agonists (TLR) and RIG-I-like-Receptor (RLR) agonists. The drug substance is RNA (ribonucleic acid). Our GMP TLR3 ligands (RIBOXXIM®, APOXXIM®, RIBOXXON®, RIBOXXOL®) are available for pharmaceutical companies or public institutions performing Phase I to III clinical trials.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.